- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00366899
Study Evaluating a 13-valent Pneumococcal Conjugate Vaccine in Infants
January 17, 2013 updated by: Wyeth is now a wholly owned subsidiary of Pfizer
A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety,Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Paediatric Vaccinations in Italy
The purpose of this study is to assess the safety, tolerability and immunogenicity of a 13-valent pneumococcal conjugate (13vPnC) vaccine compared to Prevenar (7vPnC), when given concomitantly with routine paediatric vaccinations in Italy.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
605
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Campania
-
Napoli, Campania, Italy, 80122
-
Napoli, Campania, Italy, 80139
-
-
Emilia Romagna
-
Bologna, Emilia Romagna, Italy, 40138
-
-
Lazio
-
Roma, Lazio, Italy, 00165
-
Roma, Lazio, Italy, 00100
-
-
Liguria
-
Genova, Liguria, Italy, 16132
-
-
Lombardia
-
Milan, Lombardia, Italy, 20122
-
-
Piemonte
-
Novara, Piemonte, Italy, 28100
-
-
Puglia
-
Taranto, Puglia, Italy, 74100
-
-
Sardegna
-
Sassari, Sardegna, Italy, 07100
-
-
Sicilia
-
Ragusa, Sicilia, Italy, 97100
-
-
Sicillia
-
Palermo, Sicillia, Italy, 90100
-
-
Toscana
-
Firenze, Toscana, Italy, 50132
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
2 months to 3 months (Child)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion criteria:
- Aged 3 months (75 to 105 days) at time of enrollment.
- Available for entire study period and whose parent(s)/legal guardian(s) could be reached by telephone.
- Healthy infant, as determined by medical history, physical examination, and judgment of the investigator.
- Born at greater than 32 weeks gestational age and greater than 2000 grams. Regardless of gestational age and birth weight, all subjects must have met inclusion criterion number 3.
- Parent(s)/legal guardian(s) had to be able to complete all relevant study procedures during study participation.
Exclusion criteria:
- Previous vaccination with licensed or investigational pneumococcal vaccine.
- Previous vaccination with Hib conjugate, diphtheria, tetanus, pertussis, polio, or hepatitis B vaccines.
- A previous anaphylactic reaction to any vaccine or vaccine-related component.
- Contraindication to vaccination with Hib conjugate, diphtheria, tetanus, pertussis, polio, or hepatitis B, or pneumococcal vaccines.
- Bleeding diathesis or condition associated with prolonged bleeding time that would contraindicate intramuscular injection.
- Known or suspected immune deficiency or suppression.
- History of culture-proven invasive disease caused by S pneumoniae or Hib.
- Major known congenital malformation or serious chronic disorder.
- Significant neurological disorder or history of seizure, including febrile seizure, or significant stable or evolving disorders, such as cerebral palsy, encephalopathy, hydrocephalus, or other significant disorders. Did not include resolving syndromes due to birth trauma such as Erb palsy.
- Receipt of blood products or gamma-globulin (including hepatitis B immunoglobulin and monoclonal antibodies; eg, Synagis® [MedImmune]).
- Participation in another investigational trial. Participation in purely observational studies was acceptable.
- Infant who was a direct descendant (eg, child or grandchild) of the study site personnel.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 1
13-valent pneumococcal conjugate vaccine
|
Single 0.5 mL dose of 13vPnC given at 3, 5 and 11 months of age.
|
Active Comparator: 2
7-valent pneumococcal conjugate vaccine
|
Single 0.5 mL dose of 7vPnC given at 3, 5 and 11 months of age.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Participants Reporting Pre-Specified Local Reactions
Time Frame: During the 4-day period after each dose
|
Local reactions were collected using an electronic diary.
Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement).
Swelling and redness were scaled as Any (swelling or redness present); Mild (0.5 centimeters [cm] to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (>7.0 cm).
Participants may be represented in more than 1 category.
|
During the 4-day period after each dose
|
Percentage of Participants Reporting Pre-Specified Systemic Events
Time Frame: During the 4-day period after each dose
|
Systemic events (fever ≥ 37.5 degrees Celsius [C], fever ≥ 38 C but ≤ 39 C, fever >39 C but ≤ 40 C, fever > 40 C, decreased appetite, irritability, increased sleep, decreased sleep, hives, use of medication (meds) to treat symptoms, and use of medication to prevent symptoms) were reported using an electronic diary.
Participants may be represented in more than 1 category.
|
During the 4-day period after each dose
|
Percentage of Participants Achieving Predefined Antibody Levels for Concomitant Antigen Pertussis, Hepatitis B, Haemophilus Influenzae Type b, Diphtheria, Tetanus and Polio After the 2-Dose Infant Series and After the Toddler Dose
Time Frame: One month after the infant series (6 months of age) and after the toddler dose (12 months of age)
|
Percentage of Participants achieving predefined antibody threshold levels for Pertussis Toxoid (PT) ≥5 ELISA units per milliliter (EU/mL), Filamentous Haemagglutinin (FHA) ≥5 or ≥7.82 EU/mL, and Pertactin (PRN) ≥5 EU/mL, ≥10.0 Milli-International Units Per Milliliter (mIU/mL) for Hepatitis B, Haemophilus Influenzae type b (Hib) 0.15 μg/ml, 0.01 or 0.1 IU/mL for Diphtheria, 0.1 IU/mL for Tetanus, and ≥1:8 titer for Polio (Type 1, 2, and 3) with the corresponding 95% CI for antigens are presented.
|
One month after the infant series (6 months of age) and after the toddler dose (12 months of age)
|
Geometric Mean Antibody Concentration (GMC) of Pertussis in the 13vPnC Group Relative to the 7vPnC Group After the 2-Dose Infant Series and After the Toddler Dose
Time Frame: one month after infant series dose 2 (6 months of age) and after the toddler dose (12 months of age)
|
GMC of Pertussis (PT, FHA, PRN) were measured using an anti-Bordetella pertussis enzyme-linked immunosorbent assay (ELISA).
Results were recorded in ELISA units per milliliter (EU/mL)
|
one month after infant series dose 2 (6 months of age) and after the toddler dose (12 months of age)
|
Geometric Mean Antibody Concentration (GMC) for Hepatitis B in the 13vPnC Group Relative to the 7vPnC Group After the 2-Dose Infant Series and After Toddler Dose
Time Frame: One month after the infant series (6 months of age) and the toddler dose (12 months of age)
|
GMC of anti-hepatitis B surface antigen (HBsAg)using an Food and Drug Administration (FDA) approved in vitro diagnostic kit.
|
One month after the infant series (6 months of age) and the toddler dose (12 months of age)
|
Geometric Mean Antibody Concentration (GMC) of Haemophilus Influenzae Type b (Hib) in the 13vPnC Group Relative to the 7vPnC Group After the 2-Dose Infant Series and After the Toddler Dose
Time Frame: one month after infant series dose 2 (6 months of age) and after the toddler dose (12 months of age)
|
GMC for Hib polyribosylribitol phosphate as measured by ELISA, expressed in micrograms per milliliter (μg/mL).
|
one month after infant series dose 2 (6 months of age) and after the toddler dose (12 months of age)
|
Geometric Mean Antibody Concentration (GMC) of Diptheria and Tetanus in the 13vPnC Group Relative to the 7vPnC Group After the 2-Dose Infant Series and After the Toddler Dose
Time Frame: one month after infant series dose 2 (6 months of age) and after the toddler dose (12 months of age)
|
GMC of anti-diphtheria and anti-tetanus toxoids as measured by ELISA (IU/mL).
|
one month after infant series dose 2 (6 months of age) and after the toddler dose (12 months of age)
|
Geometric Mean Antibody Concentration (GMC) of Polio Types 1, 2, and 3 in the 13vPnC Group Relative to the 7vPnC Group After the 2-Dose Infant Series and After the Toddler Dose
Time Frame: one month after infant series dose 2 (6 months of age) and after the toddler dose (12 months of age)
|
GMC of Polio as measured using a polio in vitro plaque neutralization.
|
one month after infant series dose 2 (6 months of age) and after the toddler dose (12 months of age)
|
Percentage of Participants Achieving an Antibody Level of ≥0.35 μg/mL in the 13vPnC Group After the 2-Dose Infant Series and Before the Toddler Dose
Time Frame: one month after infant series dose 2 (6 months of age) and before the toddler dose (11 months of age)
|
Percentages of Participants achieving World Health Organization (WHO) predefined antibody threshold ≥0.35μg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.
|
one month after infant series dose 2 (6 months of age) and before the toddler dose (11 months of age)
|
Geometric Mean Concentration (GMC) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody in 13vPnC Group After the 2-Dose Infant Series and Before Toddler Dose
Time Frame: One month after infant series dose 2 (6 months of age) and before the toddler dose (11 months of age)
|
Antibody GMC for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.
|
One month after infant series dose 2 (6 months of age) and before the toddler dose (11 months of age)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Participants Achieving an Antibody Level of ≥0.35 μg/mL in the 13vPnC Relative to the 7vPnC Group After the Toddler Dose
Time Frame: One month after the toddler dose (12 months of age)
|
Percentages of Participants achieving WHO predefined antibody threshold ≥0.35μg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.
|
One month after the toddler dose (12 months of age)
|
Geometric Mean Concentration (GMC) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody in 13vPnC Relative to 7vPnC Group After the Toddler Dose
Time Frame: One month after toddler dose (12 months of age)
|
Antibody GMC for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.
|
One month after toddler dose (12 months of age)
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Subjects Achieving Antibody Titer (OPA) ≥1:8 in 13vPnC Group After the 2-Dose Infant Series and the Toddler Dose
Time Frame: one month after infant series dose 2 and after the toddler dose
|
Percentage of subjects achieving functional antibody titer ≥1:8 as measured by opsonophagocytic activity assay (OPA) along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.
(This is not a geometric mean comparison as suggested by the table row heading).
|
one month after infant series dose 2 and after the toddler dose
|
Geometric Mean Antibody Titer (OPA) in 13vPnC Group After the 2-Dose Infant Series and the Toddler Dose
Time Frame: one month after infant series dose 2 and after the toddler dose
|
Antibody functionality/geometric mean titer (GMT) as measured by opsonophagocytic activity assay(OPA) for7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.
|
one month after infant series dose 2 and after the toddler dose
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
October 1, 2006
Primary Completion (Actual)
July 1, 2008
Study Completion (Actual)
July 1, 2008
Study Registration Dates
First Submitted
August 17, 2006
First Submitted That Met QC Criteria
August 18, 2006
First Posted (Estimate)
August 21, 2006
Study Record Updates
Last Update Posted (Estimate)
February 22, 2013
Last Update Submitted That Met QC Criteria
January 17, 2013
Last Verified
January 1, 2013
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 6096A1-500
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Vaccines, Pneumococcal
-
Wyeth is now a wholly owned subsidiary of PfizerCompletedVaccines, Pneumococcal | Vaccines, Pneumococcal Conjugate Vaccine
-
Vaxcyte, Inc.CompletedPneumococcal VaccinesUnited States
-
Wyeth is now a wholly owned subsidiary of PfizerCompletedVaccines, PneumococcalGermany
-
Wyeth is now a wholly owned subsidiary of PfizerCompletedPneumococcal VaccinesUnited States
-
PfizerCompletedPneumococcal Vaccines | Pneumococcal Conjugate VaccineJapan
-
VA Sierra Nevada Health Care SystemMerck Sharp & Dohme LLCNot yet recruitingImmunosuppression | Pneumococcal Vaccines
-
Maria de Lourdes de Sousa Maia, MDNot yet recruiting
-
Vaxcyte, Inc.CompletedPneumococcal VaccinesUnited States
-
Vaxcyte, Inc.Active, not recruitingPneumococcal VaccinesUnited States
-
Inventprise Inc.PATH; Canadian Center for Vaccinology; Vaccine Evaluation Center, CanadaActive, not recruitingPneumococcal VaccinesCanada
Clinical Trials on 13-valent pneumococcal conjugate vaccine
-
Beijing Zhifei Lvzhu Biopharmaceutical Co., LtdRecruitingConsistency, Immunogenicity, and Safety of Three Batches of 15-valent Pneumococcal Conjugate VaccineHealthy VolunteersChina
-
Sinovac Life Sciences Co., Ltd.RecruitingPneumococcal InfectionsChina
-
Beijing Zhifei Lvzhu Biopharmaceutical Co., LtdNot yet recruiting
-
Wyeth is now a wholly owned subsidiary of PfizerCompletedPneumococcal VaccineKorea, Republic of
-
Wyeth is now a wholly owned subsidiary of PfizerCompletedVaccines, PneumococcalGermany
-
CanSino Biologics Inc.Henan Center for Disease Control and PreventionCompletedPneumococcal Infections | Bacterial Infections | Streptococcal InfectionsChina
-
Telethon Kids InstitutePapua New Guinea Institute of Medical ResearchCompleted
-
Murdoch Childrens Research InstituteNational Health and Medical Research Council, Australia; GlaxoSmithKline; Bill... and other collaboratorsCompleted
-
PfizerCompletedPneumococcal DiseaseSpain, Poland, Hungary
-
Wyeth is now a wholly owned subsidiary of PfizerCompletedVaccines, PneumococcalSpain